tru Independence’s AbbVie ABBV Stock Holding History

tru Independence’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$415K	Buy	1,648 +59	+4%	+$12.7K	0.18%	65
2026 Q1	$346K	Sell	1,589 -17,848	-92%	-$3.96M	0.17%	73
2025 Q4	$4.44M	Sell	19,437 -32	-0.2%	-$7.29K	1.12%	43
2025 Q3	$4.51M	Buy	19,469 +155	+0.8%	+$31.6K	1.17%	42
2025 Q2	$3.59M	Buy	19,314 +207	+1%	+$38.5K	1.04%	44
2025 Q1	$4M	Buy	19,107 +799	+4%	+$155K	1.24%	39
2024 Q4	$3.25M	Sell	18,308 -164	-0.9%	-$30.2K	1.02%	42
2024 Q3	$3.65M	Sell	18,472 -16,919	-48%	-$3.16M	1.07%	46
2024 Q2	$6.07M	Buy	+35,391	New	+$5.86M	1.83%	21
2021 Q1	–	Sell	-1,434	Closed	-$154	–	298
2020 Q4	$154	Buy	1,434 +139	+11%	+$13.4K	﹤0.01%	439
2020 Q3	$113K	Sell	1,295 -9,834	-88%	-$926K	0.03%	182
2020 Q2	$1.09M	Sell	11,129 -2,747	-20%	-$242K	0.16%	106
2020 Q1	$1.06M	Hold	13,876	–	–	0.17%	95
2019 Q4	$1.06M	Buy	+13,876	New	+$1.15M	0.15%	109

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

tru Independence's ABBV Position: Q2 2026 in Review

tru Independence increased its AbbVie (ABBV) stake by 3.7% in Q2 2026, buying an estimated $12.7K and bringing the position to 1,648 shares worth $415K. The position accounts for 0.18% of the portfolio, ranked #65.

tru Independence first reported a position in ABBV in Q4 2019 and has held it in 14 quarters since. The position peaked at $6.07M in Q2 2024. 4,214 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

tru Independence held 1,648 shares of AbbVie worth $415K as of Q2 2026.
tru Independence bought 59 AbbVie shares in Q2 2026, an estimated $12.7K.
AbbVie made up 0.18% of tru Independence's portfolio in Q2 2026, its #65 holding.
tru Independence first reported a position in AbbVie in Q4 2019 and has held it in 14 quarters since.
tru Independence's AbbVie position peaked at $6.07M in Q2 2024.
4,214 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on tru Independence's 13F filing for Q2 2026, filed 10 Aug 2026.